Tobacco use is the leading preventable cause of death in the United States. Legislation empowers the FDA to regulate the manufacture, marketing, and distribution of tobacco products, and requires new warnings on cigarette packs to communicate the risks of smoking. In this supplement to an existing P30 research grant, we seek to synthesize the literature and expand the ecological validity of the controlled laboratory experiments examining the warnings'impacts. To accomplish this, we will conduct a meta-analysis of the existing experimental literature on cigarette pack warnings (Aim 1). In addition, we will conduct a large-scale RCT in which we label cigarette packs that smokers use every day with text or graphic warnings to examine the impact on smoking behavior (Aim 2). This new approach combines the strengths of laboratory experiments and field studies in evaluating warnings to achieve strong generalizability and internal validity. Participants will be 2,250 adult smokers ages 18-65 from North Carolina and California. The proposed studies will additionally examine whether the impact of cigarette pack warnings on smoking behavior differs for low-income versus higher-income smokers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA016086-38S2
Application #
8641499
Study Section
Special Emphasis Panel (ZRG1-RPHB-K (40))
Program Officer
Shafik, Hasnaa
Project Start
1997-06-01
Project End
2014-11-30
Budget Start
2013-12-01
Budget End
2014-11-30
Support Year
38
Fiscal Year
2014
Total Cost
$1,015,491
Indirect Cost
$196,163
Name
University of North Carolina Chapel Hill
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Joseph, Sarah B; Arrildt, Kathryn T; Sturdevant, Christa B et al. (2015) HIV-1 target cells in the CNS. J Neurovirol 21:276-89
Sikov, William M; Berry, Donald A; Perou, Charles M et al. (2015) Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (A J Clin Oncol 33:13-21
Blazer, Marlo; Wu, Christina; Goldberg, Richard M et al. (2015) Neoadjuvant modified (m) FOLFIRINOX for locally advanced unresectable (LAPC) and borderline resectable (BRPC) adenocarcinoma of the pancreas. Ann Surg Oncol 22:1153-9
Knight, E R W; Patel, E Y; Flowers, C A et al. (2015) ASC deficiency suppresses proliferation and prevents medulloblastoma incidence. Oncogene 34:394-402
Dellon, Evan S; Speck, Olga; Woodward, Kimberly et al. (2015) Distribution and variability of esophageal eosinophilia in patients undergoing upper endoscopy. Mod Pathol 28:383-90
Qi, Qibin; Kilpeläinen, Tuomas O; Downer, Mary K et al. (2014) FTO genetic variants, dietary intake and body mass index: insights from 177,330 individuals. Hum Mol Genet 23:6961-72
Jha, Deepak Kumar; Strahl, Brian D (2014) An RNA polymerase II-coupled function for histone H3K36 methylation in checkpoint activation and DSB repair. Nat Commun 5:3965
Guo, Shutao; Lin, C Michael; Xu, Zhenghong et al. (2014) Co-delivery of cisplatin and rapamycin for enhanced anticancer therapy through synergistic effects and microenvironment modulation. ACS Nano 8:4996-5009
Clark, Martha A; Goheen, Morgan M; Spidale, Nicholas A et al. (2014) RBC barcoding allows for the study of erythrocyte population dynamics and P. falciparum merozoite invasion. PLoS One 9:e101041
Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra et al. (2014) UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor. J Med Chem 57:7031-41

Showing the most recent 10 out of 292 publications